Form SC 13G - Statement of acquisition of beneficial ownership by individuals
13 Febbraio 2024 - 3:08AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of
1934*
Belite
Bio, Inc |
(Name of Issuer) |
|
Ordinary
shares, par value US$0.0001 per share |
(Title of Class of
Securities) |
|
07782B
104** |
(CUSIP Number) |
|
December 31,
2023 |
(Date of Event
which Requires Filing of this Statement) |
Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:
| ¨ | Rule
13d-1(b) |
| ¨ | Rule
13d-1(c) |
| x | Rule
13d-1(d) |
* The
remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject
class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover
page.
**
There is no CUSIP number assigned to the ordinary shares of the Issuer (“Ordinary Shares”). CUSIP number 07782B 104 has been
assigned to the American Depositary Shares (“ADSs”) of the Issuer, which are quoted on NASDAQ Capital Market under the symbol
“BLTE”. Each ADS represents one Ordinary Share.
The
information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18
of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act, but shall
be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 07782B 104 | SCHEDULE
13G | Page
2 of 4 Pages |
1 |
NAMES OF REPORTING PERSONS
Yu-Hsin Lin
|
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
¨
(b)
¨ |
3 |
SEC
USE ONLY
|
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Australia
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH |
5 |
SOLE VOTING POWER
2,127,822
|
6 |
SHARED VOTING POWER
|
7 |
SOLE DISPOSITIVE POWER
2,127,822
|
8 |
SHARED DISPOSITIVE POWER
0
|
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
2,127,822(1)
|
10 |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES ¨
¨ |
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
7.3%(2)
|
12 |
TYPE OF REPORTING PERSON
IN
|
|
|
|
|
| (1) | Include (i) 533,928 Ordinary Shares directly held by Yu-Hsin Lin; (ii) 105,276 Ordinary Shares underlying
share options granted to Yu-Hsin Lin that are vested or will be vested within 60 days of December 31, 2023; and (iii) 1,488,618 Ordinary
Shares indirectly held by Yu-Hsin Lin through Lin Bioscience International Ltd., which is our principal shareholder and the wholly-owned
subsidiary of our controlling shareholder Lin BioScience, Inc.(stock code: 6696.TW). |
| (2) | The percentage is calculated based upon an aggregate of (i) 29,149,444 Ordinary Shares outstanding as of December 31, 2023 as provided
by the Issuer; and (ii) 105,276 Ordinary Shares underlying share options granted to Yu-Hsin Lin that are vested or will be vested within
60 days of December 31, 2023. |
CUSIP No. 07782B 104 | SCHEDULE
13G | Page
3 of 4 Pages |
Belite Bio, Inc (the “Issuer”)
| Item 1(b) | Address of Issuer’s
Principal Executive Offices: |
12750 High Bluff Drive Suite 475,
San Diego, CA 92130
United States of America
Item 2(a) | Name of Persons Filing: |
This Schedule 13G is filed on behalf of Yu-Hsin Lin (“Reporting
Person”)
Item 2(b) | Address of Principal Business Office or, If None, Residence |
The business address of the Reporting Person is 36F.,
No. 68, Sec. 5, Zhongxiao E. Rd., Xinyi Dist., Taipei City 110, Taiwan
Yu-Hsin Lin is a citizen of Australia
Item 2(d) | Title of Class of Securities: |
Ordinary Shares, par value $0.0001 per share
07782B 104
Item 3. | Statement Filed Pursuant to Rule 13d-1(b) or 13d-2(b)
or (c): |
Not applicable.
The information for the Reporting Person contained in
rows 5-11 of the cover page and Item 2(a) is incorporated herein by reference.
Item 5. | Ownership of Five Percent
or Less of a Class |
Not applicable.
Item 6. | Ownership of More Than Five
Percent on Behalf of Another Person |
Not applicable.
Item 7. | Identification and Classification
of Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company
or Control Person |
Not applicable.
Item 8. | Identification and Classification of Members of the
Group |
Not applicable.
Item 9. | Notice of Dissolution of Group |
Not applicable.
Not applicable.
CUSIP No. 07782B 104 | SCHEDULE
13G | Page
4 of 4 Pages |
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete
and correct.
Dated: February 12, 2024 |
|
|
|
|
Yu-Hsin Lin |
|
|
|
By: |
/s/Yu-Hsin Lin |
|
Name: |
Yu-Hsin Lin |
|
Title: |
Chief Executive Officer and Chairman |
Grafico Azioni Belite Bio (NASDAQ:BLTE)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Belite Bio (NASDAQ:BLTE)
Storico
Da Nov 2023 a Nov 2024